Reconsidering clinical outcomes in Multiple Sclerosis: Relapses, impairment, disability and beyond

Journal of the Neurological Sciences

Volumn 274, Issue 1-2, 2008, Pages 76-79

  D'Souza, M ^a   Kappos, L ^a   Czaplinski, A ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Clinical trials; EDSS; MSFC; Multiple Sclerosis; Outcome measures; Relapses

Indexed keywords

BETA1A INTERFERON; IMMUNOGLOBULIN; INTERFERON BETA SERINE; ISONIAZID;

ARTICLE; CLINICAL TRIAL; DISABILITY; DRUG EFFICACY; EXPANDED DISABILITY STATUS SCALE; FUNCTIONAL ASSESSMENT; HUMAN; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY CONTROL; RELAPSE;

CLINICAL TRIALS AS TOPIC; DISABILITY EVALUATION; HUMANS; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 53049101849     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2008.08.023     Document Type: Article

References (32)

1. Comi G., and Filippi M. Clinical trials in multiple sclerosis: methodological issues. Curr Opin Neurol 18 3 (2005) 245-252
2. Lublin F. Multiple sclerosis trial designs for the 21st century: building on recent lessons. J Neurol 252 Suppl 5 (2005) v46-53
3. Ebers G.C., Heigenhauser L., Daumer M., Lederer C., and Noseworthy J.H. Disability as an outcome in MS clinical trials. Neurology (2008)
4. Schumacher G.A., Beebe G., Kibler R.F., Kurland L.T., Kurtzke J.F., McDowell F., et al. Problems of experimental trials of therapies in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci 122 1 (1965) 552-568
5. Vollmer T. The natural history of relapses in multiple sclerosis. J Neurol Sci 256 Suppl 1 (2007) S5-13
6. Tremlett H., Zhao Y., Joseph J., and Devonshire V. Relapses in multiple sclerosis are age and time-dependent. J Neurol Neurosurg Psychiatr (2008)
7. Fazekas F., Deisenhammer F., Strasser-Fuchs S., Nahler G., and Mamoli B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 349 9052 (1997) 589-593
8. Kappos L. Critical comment: randomized placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Int MS J 4 (1997) 43
9. Faria A.M., and Weiner H.L. Oral tolerance: mechanisms and therapeutic applications. Adv Immunol 73 (1999) 153-264
10. Martínez-Yélamos S., Martínez-Yélamos A., Martín Ozaeta G., Casado V., Carmona O., and Arbizu T. Regression to the mean in multiple sclerosis. Mult Scler 12 6 (2006) 826-829
11. Patzold U. Multiple Sklerose: Verlauf und Therapie; Ergebnisse einer prospektiven Untersuchung (1985), Thieme, Stuttgart
12. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 11 (1983) 1444-1452
13. Goodkin D.E., Cookfair D., Wende K., Bourdette D., Pullicino P., Scherokman B., et al. Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Multiple Sclerosis Collaborative Research Group. Neurology 42 4 (1992) 859-863
14. Kappos, Wu, Lechner-Scott, Neurostatus DVD/Website: www.neurostatus.net.
15. Cohen J.A., Cutter G.R., Fischer J.S., Goodman A.D., Heidenreich F.R., Jak A.J., et al. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol 58 6 (2001) 961-967
16. Hoogervorst E.L., Kalkers N.F., van Winsen L.M.L., Uitdehaag B.M., and Polman C.H. Differential treatment effect on measures of neurologic exam, functional impairment and patient self-report in multiple sclerosis. Mult Scler 7 5 (2001) 335-339
17. Kappos L., Freedman M.S., Polman C.H., Edan G., Hartung H.P., Miller D.H., et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 370 9585 (2007) 389-397
18. Balcer L.J., Baier M.L., Cohen J.A., Kooijmans M.F., Sandrock A.W., Nano-Schiavi M.L., et al. Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite. Neurology 61 10 (2003) 1367-1373
19. Vaney C., Vaney S., and Wade D.T. SaGAS, the Short and Graphic Ability Score: an alternative scoring method for the motor components of the Multiple Sclerosis Functional Composite. Mult Scler 10 2 (2004) 231-242
20. Ravnborg M., Grønbech-Jensen M., and Jønsson A. The MS Impairment Scale: a pragmatic approach to the assessment of impairment in patients with multiple sclerosis. Mult Scler 3 1 (1997) 31-42
21. Sharrack B., and Hughes R.A. The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis. Mult Scler 5 4 (1999) 223-233
22. Mumford C.J., and Compston A. Problems with rating scales for multiple sclerosis: a novel approach-the CAMBS score. J Neurol 240 4 (1993) 209-215
23. Amato M.P., and Portaccio E. Clinical outcome measures in multiple sclerosis. J Neurol Sci 259 1-2 (2007) 118-122
24. Poser S., Bauer H.J., and Poser W. Prognosis of multiple sclerosis. Results from an epidemiological area in Germany. Acta Neurol Scand 65 4 (1982) 347-354
25. Wingerchuk D.M., Noseworthy J.H., and Weinshenker B.G. Clinical outcome measures and rating scales in multiple sclerosis trials. Mayo Clin Proc 72 11 (1997) 1070-1079
26. Roxburgh R.H.S.R., Seaman S.R., Masterman T., Hensiek A.E., Sawcer S.J., Vukusic S., et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 64 7 (2005) 1144-1151
27. Herbert J. A new severity-based classification system for multiple sclerosis. Neurology 70 1 (2008) 269; P05.067
28. Daumer M., Thaler K., Kruis E., Feneberg W., Staude G., and Scholz M. Steps towards a miniaturized, robust and autonomous measurement device for the long-term monitoring of patient activity: ActiBelt. Biomedizinische Technik. Biomed Eng 52 1 (2007) 149-155
29. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43 4 (1993) 655-661
30. Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., Richert J.R., Salazar A.M., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39 3 (1996) 285-294
31. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998;352(9139):1498-1504.
32. Johnson K.P., Brooks B.R., Cohen J.A., Ford C.C., Goldstein J., Lisak R.P., et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45 7 (1995) 1268-1276